Atherosclerotic Cardiovascular Disease Epidemiology

• DelveInsight’s analyst projects that among the total cases of 7MM approximately 47% of individuals were from the US. As per our estimations, in 2023, the US accounted for 26 million diagnosed prevalent cases of ASCVD.
• As per DelveInsight’s analysis, EU4 and the UK comprised around 38% of the diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease in 2023 among the 7MM.
• DelveInsight’s 2023 analysis for the EU4 and UK indicates a higher prevalence of diagnosed ASCVD cases in males, nearly 12,601 thousand cases, compared to 8,645 thousand cases in females. Males typically experience ASCVD earlier and face an increased risk of coronary heart disease (CHD) relative to females.
• As per DelveInsight’s analyst, in Japan the number of cases for age-specific diagnosed prevalence cases of ASCVD in 2023 were nearly  1,641 thousand cases, 5,466 cases, and 1,100 cases for age groups 18–44 years, 45–64 years, and 65 years and above, respectively, during the study period (2021-2034).

DelveInsight’s “Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology Forecast – 2034” report delivers an in-depth understanding of Atherosclerotic Cardiovascular Disease (ASCVD), historical and forecasted epidemiology of Atherosclerotic Cardiovascular Disease (ASCVD) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Atherosclerotic Cardiovascular Disease (ASCVD) Understanding

Atherosclerotic Cardiovascular Disease (ASCVD) Overview

ASCVD is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include coronary artery disease (CAD), cerebrovascular disease (stroke), and peripheral arterial disease (PAD).

The development of ASCVD is influenced by a number of risk factors, such as poor diet, inactivity, cigarette use, obesity, family history, and alcohol abuse. The early stages of ASCVD are without symptoms, but later on as the artery narrows and blood flow is reduced, symptoms start to show. The type of artery that is affected and how much blood flow is impeded may also alter the symptoms. Angina, cold chills, dizziness, acute exhaustion, shortness of breath, and heart palpitations are a few typical symptoms.

Atherosclerotic Cardiovascular Disease (ASCVD) Diagnosis

In addition to symptoms, risk assessment is also used to make the diagnosis of ASCVD. Apolipoprotein E [APOE], LDLR, APOB, PCSK9, or LDLRAP1 genes; genotyping to study variations in contributing genes; and morphological examinations (ultrasonography, computed tomography, magnetic resonance imaging/angiography, or catheterization) are typically used to make a clinical diagnosis of ASCVD. Genetic testing, biomarker testing, and imaging can all be used to confirm an ASCVD diagnosis if a doctor has a suspicion. However, the cost and accessibility of genetic testing and biomarker testing may restrict their use.

Further details related to diagnosis are provided in the report...

Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology

For the purpose of designing the patient-based model for Atherosclerotic Cardiovascular Disease (ASCVD), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease, (ASCVD), Gender-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD), Age-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD)  and Comorbidity-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD), in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2021 to 2034.

As per DelveInsight’s estimations, the total diagnosed prevalent cases of ASCVD in the 7MM was approximately 56 million cases in 2023 and are projected to increase during the forecast period.

• In 2023, among the 7MM, Japan recorded the second highest number of diagnosed prevalent cases of ASCVD, with approximately 8,206 thousand cases.
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of ASCVD, with nearly 5,732 thousand cases, followed by France and Italy in 2023. On the other hand, Spain had the lowest prevalent population in the European region in 2023.
• The highest proportion of ASCVD cases was observed in the 65 years and above age group in the 7MM, while the least cases were in the age group 18–44 years.
• The United States had the highest number of diagnosed cases of ASCVD in males compared to females. In 2023, of all ASCVD cases, approximately 56% were males, while around 44% of females were diagnosed with the condition.
• The comorbidity-specific cases of ASCVD were divided into recent ACS, ischemic stroke, PAD, other CHD, and other comorbidities comprising CKD. PAD had the highest number of cases, nearly 3,168 thousand in 2023 in Japan.
• Comorbidity-specific Atherosclerotic Cardiovascular Disease (ASCVD) Cases in the US

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Rollins School of Public Health, Emory University, Atlanta, Georgia, US; Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany; Cardiovascular Prevention Institute, Paris, France; Maria Cecilia Hospital, GVM Care & Research, Lugo, Italy; University Hospital Ramón y Cajal, Madrid, Spain; Teikyo Academic Research Center, Teikyo University, Itabashi-ku, Tokyo; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of executive summary, descriptive overview of Atherosclerotic Cardiovascular Disease (ASCVD) explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Atherosclerotic Cardiovascular Disease (ASCVD) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD)
• Gender-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD)
• Age-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD)
• Comorbidity-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD)

Atherosclerotic Cardiovascular Disease (ASCVD) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology Segmentation

Atherosclerotic Cardiovascular Disease (ASCVD) Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Atherosclerotic Cardiovascular Disease (ASCVD)? What will be the growth opportunities across the 7MM concerning the patient population of Atherosclerotic Cardiovascular Disease (ASCVD)?
• What is the historical and forecasted Atherosclerotic Cardiovascular Disease (ASCVD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the prevalent cases of Atherosclerotic Cardiovascular Disease (ASCVD) in Japan lower than the US?
• Which country has a high patient share for Atherosclerotic Cardiovascular Disease (ASCVD)?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Atherosclerotic Cardiovascular Disease (ASCVD) prevalent cases in varying geographies over the coming years.
• A detailed overview of Gender and Age-specific prevalence of Atherosclerotic Cardiovascular Disease (ASCVD), along with Comorbidity-specific prevalence of Atherosclerotic Cardiovascular Disease (ASCVD).
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions  

1.         What is the forecast period covered in the report?

The Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2.         Out of all EU4 countries and the UK, which country had the highest population of Atherosclerotic Cardiovascular Disease (ASCVD) cases in 2023?

The highest cases of Atherosclerotic Cardiovascular Disease (ASCVD) was found in the Germany among EU4 and the UK in 2023.

3.         How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4.         Out of all 7MM countries, which country had the highest population of Atherosclerotic Cardiovascular Disease (ASCVD) cases in 2023?

The highest cases of Atherosclerotic Cardiovascular Disease (ASCVD) were found in the US among the 7MM in 2023.